@article{3003168,
    title = "The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study",
    author = "Psaltis, D. and Settas, L. and Georgiadis, A. and Koukli, E. and Bounas, A. and Livieratos, A. and Petrikkou, E. and Kalogiannaki, H. and Repa, A. and Vassilopoulos, D. and Sidiropoulos, P.",
    journal = "Rheumatology International",
    year = "2022",
    publisher = "Springer Science and Business Media Deutschland GmbH",
    issn = "0172-8172, 1437-160X",
    doi = "10.1007/s00296-021-05073-1",
    abstract = "This study aimed at assessing the impact of golimumab on health-related quality of life (HRQoL) and other patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) in real-world settings. GO-Q was an observational, prospective, 12-month study, which recruited patients with moderate-to-severely active RA initiating golimumab treatment per label in rheumatology clinics and private practices. Primary endpoint was the change in PROs [EuroQol-5 Dimensions-3 Levels (EQ-5D-3L) questionnaire, Health Assessment Questionnaire Disease Index (HAQ-DI), and Work Productivity and Activity Index for RA (WPAI:RA)] after 12 months of treatment. Other endpoints included Disease Activity Score for 28 joints with erythrocyte sedimentation rate (DAS28-ESR), healthcare resource utilization, and golimumab adherence. Changes in continuous variables from baseline were evaluated with the paired t test. One hundred forty-five patients were recruited. The mean [standard deviation (SD)] EQ-5D-3L index increased significantly at 12 months versus baseline [from 0.427 (0.206) to 0.801 (0.229); p < 0.0001], with changes as early as 3 and 6 months (both p < 0.0001). Accordingly, there were statistically significant changes in all WPAI:RA domains from baseline to 3, 6, and 12 months (p < 0.0001). Patients’ function improved gradually from the third month until the end of follow-up (p < 0.0001 for all time-points). Thirty (27.3%) and 60 (54.6%) patients achieved remission (DAS28-ESR < 2.6) and low disease activity (DAS28-ESR ≤ 3.2), respectively, at 12 months. Adherence rate to golimumab was high (mean [SD] 90.3% (7.5) at 12 months). In patients with moderate-to-severely active RA, golimumab significantly improved HRQoL, physical function, and work productivity and activity, with improvements in disease activity over 12 months in real-world settings. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature."
}